Cargando…
S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428422/ http://dx.doi.org/10.1097/01.HS9.0000967800.55471.36 |
| _version_ | 1785090465361559552 |
|---|---|
| author | Sureda, Anna Falchi, Lorenzo Leppa, Sirpa Vermaat, Joost Holte, Harald Hutchings, Martin Lugtenburg, Pieternella de Vos, Sven Abrisqueta, Pau Nijland, Marcel Merryman, Reid W. Christensen, Jacob Haaber Wahlin, Bjorn Linton, Kim Wang, Liwei Abbas, Aqeel Rana, Ali Quadri, Syed Belada, David |
| author_facet | Sureda, Anna Falchi, Lorenzo Leppa, Sirpa Vermaat, Joost Holte, Harald Hutchings, Martin Lugtenburg, Pieternella de Vos, Sven Abrisqueta, Pau Nijland, Marcel Merryman, Reid W. Christensen, Jacob Haaber Wahlin, Bjorn Linton, Kim Wang, Liwei Abbas, Aqeel Rana, Ali Quadri, Syed Belada, David |
| author_sort | Sureda, Anna |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428422 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284222023-08-17 S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS Sureda, Anna Falchi, Lorenzo Leppa, Sirpa Vermaat, Joost Holte, Harald Hutchings, Martin Lugtenburg, Pieternella de Vos, Sven Abrisqueta, Pau Nijland, Marcel Merryman, Reid W. Christensen, Jacob Haaber Wahlin, Bjorn Linton, Kim Wang, Liwei Abbas, Aqeel Rana, Ali Quadri, Syed Belada, David Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428422/ http://dx.doi.org/10.1097/01.HS9.0000967800.55471.36 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Sureda, Anna Falchi, Lorenzo Leppa, Sirpa Vermaat, Joost Holte, Harald Hutchings, Martin Lugtenburg, Pieternella de Vos, Sven Abrisqueta, Pau Nijland, Marcel Merryman, Reid W. Christensen, Jacob Haaber Wahlin, Bjorn Linton, Kim Wang, Liwei Abbas, Aqeel Rana, Ali Quadri, Syed Belada, David S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS |
| title | S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS |
| title_full | S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS |
| title_fullStr | S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS |
| title_full_unstemmed | S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS |
| title_short | S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS |
| title_sort | s222: epcoritamab with rituximab + lenalidomide (r2) provides durable responses in patients with high-risk follicular lymphoma, regardless of pod24 status |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428422/ http://dx.doi.org/10.1097/01.HS9.0000967800.55471.36 |
| work_keys_str_mv | AT suredaanna s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT falchilorenzo s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT leppasirpa s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT vermaatjoost s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT holteharald s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT hutchingsmartin s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT lugtenburgpieternella s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT devossven s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT abrisquetapau s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT nijlandmarcel s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT merrymanreidw s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT christensenjacobhaaber s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT wahlinbjorn s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT lintonkim s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT wangliwei s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT abbasaqeel s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT ranaali s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT quadrisyed s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status AT beladadavid s222epcoritamabwithrituximablenalidomider2providesdurableresponsesinpatientswithhighriskfollicularlymphomaregardlessofpod24status |